Hepatocellular carcinoma occurrence does not differ between interferon‐based and interferon‐free treatment with liver histological assessment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Hepatocellular carcinoma occurrence does not differ between interferon‐based and interferon‐free treatment with liver histological assessment

Published:2020-01-08 Issue:3 Volume:50 Page:313-320
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Tahata Yuki¹,Sakamori Ryotaro¹^ORCID,Urabe Ayako¹,Yamada Ryoko¹,Ohkawa Kazuyoshi²,Hiramatsu Naoki³,Hagiwara Hideki⁴,Oshita Masahide⁵,Hijioka Taizo⁶,Tamura Shinji⁷,Imai Yasuharu⁸,Kodama Takahiro¹^ORCID,Hikita Hayato¹^ORCID,Tatsumi Tomohide¹,Takehara Tetsuo¹^ORCID

Affiliation:

1. Department of Gastroenterology and HepatologyOsaka University Graduate School of Medicine Suita Japan

2. Osaka International Cancer Institute Osaka Japan

3. Osaka Rosai Hospital, Sakai Osaka Japan

4. Kansai Rosai Hospital Amagasaki Japan

5. Osaka Police Hospital Osaka Japan

6. National Hospital Organization Osaka Minami Medical Center Kawachinagano Japan

7. Minoh City Hospital Minoh Japan

8. Ikeda Municipal Hospital Ikeda Japan

Funder

Gilead Sciences

Janssen Pharmaceuticals

Japan Agency for Medical Research and Development

Ministry of Health, Labour and Welfare

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13454

Reference28 articles.

1. Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C

2. Real‐world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment‐naive, genotype 1 hepatitis C‐infected patients

3. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System

4. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

5. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis;Hepatology International;2024-07-05

2. Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies;Scientific Reports;2023-03-01

3. Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis;Hepatology Research;2022-12-22

4. Improved Liver Function After Sustained Virologic Response Enhanced Prognosis in Hepatitis C with Compensated Advanced Liver Fibrosis;Digestive Diseases and Sciences;2022-12-16

5. Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis;Hepatology Research;2022-07-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3